source
- UCB to buy Candid Therapeutics for up to $2.2 billion, targeting bispecific antibodies for autoimmune diseaseUCB announced a deal to acquire Candid Therapeutics, a startup focused on bispecific antibody drugs, for an upfront payment of $2 billion with up to $200 million in future milestones. The transacti…
- UCB commits $2 billion to Candid's T cell engager program for autoimmune diseasesUCB, a long standing European pharmaceutical company, announced a $2 billion investment in Candid, a biotech focused on T cell engager therapies aimed at autoimmune conditions. The deal reflects U…